Randomised, double-blind controlled trial by dose reduction of implanted intrathecal morphine delivery in chronic non-cancer pain by Raphael, Jon H. et al.
 
 
University of Birmingham
Randomised, double-blind controlled trial by dose
reduction of implanted intrathecal morphine
delivery in chronic non-cancer pain
Raphael, Jon H.; Duarte, Rui; Southall, Jane L.; Nightingale, Peter; Kitas, George D.
DOI:
10.1136/bmjopen-2013-003061
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Raphael, JH, Duarte, R, Southall, JL, Nightingale, P & Kitas, GD 2013, 'Randomised, double-blind controlled trial
by dose reduction of implanted intrathecal morphine delivery in chronic non-cancer pain', BMJ open, vol. 3, no.
7, e003061. https://doi.org/10.1136/bmjopen-2013-003061
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Eligibility for repository: Checked on 07/12/2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Randomised, double-blind controlled
trial by dose reduction of implanted
intrathecal morphine delivery in chronic
non-cancer pain
Jon H Raphael,1,2 Rui V Duarte,1,2 Jane L Southall,2 Peter Nightingale,3
George D Kitas4
To cite: Raphael JH,
Duarte RV, Southall JL, et al.
Randomised, double-blind
controlled trial by dose
reduction of implanted
intrathecal morphine delivery
in chronic non-cancer pain.
BMJ Open 2013;3:e003061.
doi:10.1136/bmjopen-2013-
003061
▸ Prepublication history and
additional material for this
paper is available online. To
view these files please visit
the journal online
(http://dx.doi.org/10.1136/
bmjopen-2013-003061).
Received 15 April 2013
Revised 3 July 2013
Accepted 4 July 2013
1Faculty of Health,
Birmingham City University,
Birmingham, UK
2Department of Pain
Management, Russells Hall
Hospital, Dudley, UK
3Wolfson Computer
Laboratory, University
Hospitals Birmingham,
Birmingham, UK
4Department of
Rheumatology, Russells Hall
Hospital, Dudley, UK
Correspondence to
Professor Jon H Raphael;
jon.raphael@bcu.ac.uk
ABSTRACT
Objective: This study aimed to investigate the efficacy
of intrathecal morphine in the long term by
hypothesising that a reduction of the intrathecal opioid
dose following long-term administration would
increase the level of pain intensity.
Design: Randomised, double-blind, controlled, parallel
group trial.
Setting: Department of Pain Management, Russells
Hall Hospital, Dudley, UK.
Participants: 24 patients with non-cancer pain
implanted with morphine reservoirs were assessed for
eligibility.
Interventions: Participants were randomly allocated
to one of two parallel groups in which one of the
groups had no change in morphine dose and the other
group had a small reduction (20%) in dosage every
week during a 10-week follow-up.
Outcome: Primary outcomes were visual analogue
scale (VAS) pain score change and withdrawal from the
study due to lack of efficacy.
Results: 9 of the patients assessed for eligibility
declined to participate in the study. 15 patients were
randomised to control (n=5) or intervention (n=10) and
included in an intention-to-treat analysis. Owing to
worsening of pain, seven patients withdrew from the
study prematurely. None knew prior to withdrawal which
arm of the study they were in, but all turned out to be in
the dose-reduction arm. The calculation of dropout rates
between groups indicated a significant statistical
difference (p=0.026) and recruitment was ceased. The
VAS change between baseline and the last observation
was smaller in the control group (median, Mdn=11) than
in the intervention group (Mdn=30.5), although not
statistically significant, Z=−1.839, p=0.070; r=−0.47.
Within groups, VAS was significantly lower at baseline
(Mdn=49.5) than at the last observation (Mdn=77.5) for
the reduction group, Z=−2.805, p=0.002; r=−0.627 but
not for the control group (p=0.188).
Conclusions: This double-blind randomised controlled
trial of chronic intrathecal morphine administration
suggests the effectiveness of this therapy for the
management of chronic non-cancer pain. However,
owing to the small number of patients completing the
study (n=8), further studies are warranted.
Trial registration: International Standard Randomised
Controlled Trials Centre (ISRCTN 33733462).
ARTICLE SUMMARY
Article focus
▪ Recent systematic reviews were unable to find
randomised controlled trials evaluating the
effectiveness of long-term intrathecal drug deliv-
ery systems for the management of chronic non-
cancer pain.
▪ We aimed to investigate if a small decrease in
the intrathecal morphine dose leads to an
increase in reported pain scores in patients with
chronic non-cancer pain undertaking long-term
intrathecal morphine.
▪ The randomised controlled trial design would
allow investigation of the long-term efficacy of
intrathecal morphine delivery.
Key messages
▪ Statistically and clinically significant increases in
pain intensity were observed for patients rando-
mised to have intrathecal morphine dose
reduction.
▪ The findings of this study suggest the efficacy of
intrathecal morphine delivery for the manage-
ment of chronic non-cancer pain.
Strengths and limitations of this study
▪ To our knowledge, this is the first randomised
controlled trial investigating the efficacy of intra-
thecal drug delivery systems for the management
of chronic non-cancer pain.
▪ By investigating patients with intrathecal delivery
for a minimum of 12 months, this study is not
confounded by the need for dose titration and
the non-specific psychological effects of a major
intervention.
▪ The limitations of this study include the small
sample size as well as being conducted in a
single centre.
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INTRODUCTION
Opioid receptors were identiﬁed in the spinal cord in
1973.1 Subsequent animal studies demonstrated that
intrathecal (IT) opioids produce powerful and highly
selective analgesia.2 IT opioids exert their analgesic
effect presynaptically and postsynaptically by reducing
neurotransmitter release and by hyperpolarising the
membranes of neurones in the dorsal horn, thus inhibit-
ing pain transmission.3
The technique of intrathecal drug delivery (ITDD) is
based on the principle that effective analgesia can be
achieved by the action of some drugs at the dorsal horn
and adequate concentrations cannot be achieved by sys-
temic administration, or only by high systemic doses.
Delivery of the drug by the ITroute is a means of achieving
these enhanced therapeutic effects. The smaller doses
needed for ITadministration also allow a reduction in side
effects compared to systemic administration. Following the
ﬁrst clinical use of epidural4 and ITopioids,5 Cousins et al6
used the expression ‘selective spinal analgesia’ to describe
the phenomenon that spinally administered opioids could
produce a speciﬁc analgesic effect with few motor, sensory
or autonomic side effects. It was subsequently demon-
strated that the analgesic effect was, in the main, due to
the uptake of the opioid directly into the spinal cord and
cerebrospinal ﬂuid.3
The key indications for ITDD systems are chronic pain
unresponsive to curative medical or surgical measures
and to more conservative palliative measures, including
systemic analgesics, physical therapies, psychological
therapies, perineural injection procedures and nerve
lesioning procedure. Pathologies for pain are broad and
only exclude psychogenic pains; they can be due to can-
cerous or non-malignant pathologies. Morphine is con-
sidered the ‘gold standard’ medication for ITDD systems
because of its stability, receptor afﬁnity and extensive
experience of using the drug by this route.7
For chronic non-malignant pain, it is strongly recom-
mended that patients have a comprehensive psycho-
logical assessment8 to: (1) assess possible concurrent
psychopathology (eg, severe affective disorder, body dys-
morphia and procedural fears) that might impede suc-
cessful implantation and (2) consider what additional
individualised preparation might be advisable for the
patient.9 Cognitive behavioural therapy should not be
excluded as a subsequent treatment option. It may
ensure that the reduction in pain severity expected as a
result of the ITDD system is capitalised on by the devel-
opment of reduced pain related behaviours and
increased activity in a range of adaptive behaviours.
The ﬁrst reservoir for IT analgesic delivery was
implanted in 1981,10 and since then continuous IT anal-
gesia using opioids and other analgesics has become a
recognised therapy for the management of severe and
otherwise intractable chronic pain despite a lack of well-
controlled studies. A 3-year prospective study of IT
opioid treatment for chronic non-cancer pain showed
that when patients with extremely severe pain problems
are selected for ITDD, they are likely to improve with
the therapy but their overall severity of pain and symp-
toms still remains high.11 At least minimally clinically
important changes in pain intensity were observed in
95% of participants in a recent study with a mean
follow-up duration of 13 years.12 Improvements were also
observed in sensory and psychosocial outcomes.
Recent systematic reviews were unable to ﬁnd rando-
mised controlled trials (RCTs) evaluating the effective-
ness of long-term ITDD systems for the management of
chronic non-cancer pain.13 14 Overall, the use of IT
opioid administration seems beneﬁcial, but the current
available literature is too sparse to draw deﬁnite conclu-
sions mainly due to the quality of the evidence. A system-
atic review of multiple well-designed RCTs is considered
the highest level of evidence for the efﬁcacy of pain
treatment, followed by a well-designed RCT of adequate
size as the next best level of evidence.15 To our knowl-
edge, there is only one such study of IT opioids and that
is conﬁned to cancer pain.16
In the absence of strong supporting evidence for the
use of IT opioids for chronic non-cancer pain, the
therapy must be balanced against its risks as
procedure-related complications have been reported to
occur at a rate of 0.29 events/patient-year and catheter-
related complications at a rate of 0.05 events/patient-
year.17 Possible infections include meningitis, epidural
abscess, pump pocket infection or pump reservoir infec-
tion. The rate of meningitis reported by studies ranged
from 2.3% to 15.4% and for wound infections from
4.2% to 8.8%.18 When considering only non-cancer pain
studies, the percentage of patients with meningitis
ranged from 0% to 4% and for those with wound infec-
tions, from 0% to 22%.19 Furthermore, less common but
serious events of permanent neurological injury can
occur due to the development of opioid-associated
granulomata. The incidence for this adverse event has
been reported as 0.04% after 1 year, increasing to 1.15%
after 6 years.20 The management of different adverse
events is varied as some acute side effects may resolve
with time (eg, nausea, vomiting, dizziness or itching).
Recommendations for aftercare, ongoing care, preven-
tion and management of potential complications and
side effects have been described previously.8 18
We had previously undertaken a prospective controlled
study of single-dose morphine compared with saline in
patients with chronic non-malignant pain and demon-
strated spinal morphine to be efﬁcacious in the short term
for patients who responded to systemic morphine but in
whom the side effects had become intolerable.21 The
current study aimed to investigate the efﬁcacy of IT mor-
phine in the long term by hypothesising that a reduction
of the IT opioid dose following long-term administration
would increase the level of pain intensity. Our primary
outcome was the visual analogue pain score change and
withdrawal from the study due to the lack of efﬁcacy.
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METHODS
Study design and participants
We conducted a single-centre, double-blind, equal ran-
domisation (1:1), dose reduction, controlled, parallel
group study. All participants provided written informed
consent. The original protocol anticipated using diamor-
phine, but between the trial approval and start of the
trial, the practice changed to using morphine and the
protocol was amended to reﬂect this.
Treatment strategies for the management of chronic pain
start with the lowest risk and least invasive intervention and
progress if a treatment is not effective. The ITDD system is a
last-resort treatment to treat severe chronic pain because of
their invasive nature, concerns about long-term opioid use
and the possible complications related to the procedure. It
is considered for use in patients with chronic non-cancer
pain after more conventional treatments have failed (eg,
pharmacotherapy, transcutaneous electrical stimulation or,
in some cases, spinal cord stimulation) and in those who
respond to systemic opioids but where the side effects have
become intolerable. Patient suitability is also determined by
a multidisciplinary team assessment that includes a clinical
psychologist. A biopsychosocial history is performed in
which factors such as organic cause of pain, topography,
duration of pain, pain intensity, coping strategies, social
support, medico-legal matters, history of anxiety and/or
depression, previous treatments, and drug and/or alcohol
abuse are taken into consideration. Where there is a dis-
crepancy across the clinical team comprising a physician, a
physiotherapist, a psychologist and a specialist nurse, a case
conference is set up to include the family physician and
other psychologists, physiotherapists and physicians not dir-
ectly involved in IT therapy.
Following multidisciplinary assessment, all patients
have an inpatient trial of IT therapy prior to implant-
ation. This is conducted by a repeated bolus of mor-
phine and saline in a single-blind fashion.21 Patients
reporting greater than 50% relief with morphine and
less with saline are selected for the ITDD systems.
Chronic dosing is extrapolated and titrated at reﬁlls
(approximately two per month initially). A small
increase in the opioid dose may be necessary to main-
tain adequate pain control. Recent observations indicate
that signiﬁcant differences cease following year 3 of
therapy suggesting stability.12 Additional IT drugs were
added if the level of analgesia is inadequate as per the
polyanalgesic consensus conference algorithm.22
Adjuvant IT medication, such as bupivacaine, may con-
tribute to achieving better pain control and maintaining
low IT morphine doses in patients with cancer23 and
without cancer.24
Eligible participants were adults aged 18 years or over
with implanted IT reservoirs of programmable type
(SynchroMed, Medtronic Ltd) receiving IT morphine for
non-cancer pain and having had infusion for
≥12 months. Patients had reported a stable level of anal-
gesia with the pump, based on their attendance for
pump reﬁlls at which the dose did not change and they
reported analgesia. In view of the need for weekly attend-
ance during the study, only those patients living within a
short time journey from the hospital, with access to trans-
port and limited comorbidities, were considered.
The pain nurse approached eligible patients for
consent and the patients were randomly assigned by
computer-generated randomisation (PN) to one of the
two parallel groups in which one of the groups had no
change in the morphine dose (control group) and the
other group had a small reduction (20%) in the preced-
ing week’s dose every week during participation in the
study (intervention group). The allocation sequence was
received in sequentially numbered, opaque and sealed
envelopes to ensure that the sequence was concealed.
Patients were unaware as to which group they were in, as
the dose alteration or no change was conducted by tel-
emetry with the screen not visible to the patient. The tel-
emetry was conducted by a physician ( JHR) who was the
only investigator aware of the allocation. Pain scores and
other outcome measures were collected by a researcher
(RVD) blinded to the allocation of the patients.
Outcome measures
Primary outcome measures were the visual analogue scale
(VAS)25 score for pain and withdrawal from the study.
Secondary outcome measures were functional and psycho-
logical measures based on the Oswestry Disability Index
(ODI),26 Hospital Anxiety and Depression (HAD) scale27
and Coping Strategies Questionnaire (CSQ).28 Participants
were evaluated at baseline and each week during participa-
tion in the study. VAS and ODI were collected on a weekly
basis. HAD and CSQ were collected fortnightly.
Patients were asked to rate their average pain intensity
during the previous week using VAS. VAS consists of a
100 mm straight line with anchors at its ends labelled as
no pain and worst pain imaginable. It is a recognised
method for the assessment in variation of pain inten-
sity.25 29 Clinically important changes were classiﬁed in
accordance with a consensus statement that established a
10–20% decrease as minimally important, ≥30% as mod-
erately important and ≥50% as a substantial change.30
ODI is used to assess the level of pain interference
with various activities of daily living. It is a valid measure
of condition-speciﬁc disability.31 ODI consists of 10
items/activities with six levels (range 0–5). The scoring
of this questionnaire was calculated as recommended by
Fairbank and Pynsent.31
The HAD scale is a self-report rating scale of 14 items
with four levels (range 0–3). This scale is used to screen
for anxiety and depression (7 intermingled items for
each subscale). The total score for each subscale is the
sum of the respective seven items (ranging from 0 to
21). The HAD scale is considered a valid instrument for
detecting states of anxiety and depression.32
CSQ is a self-report instrument to assess the active and
passive coping skills of patients with chronic pain.33 It
includes cognitive coping strategies (diverting attention,
reinterpreting pain sensation, catastrophising, ignoring
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pain sensations, praying or hoping and coping self-
statements), behavioural coping strategies (increasing
activity level) and effectiveness ratings (control over pain
and ability to decrease pain). The scores of these sub-
scales result in three factors that account for 68% of the
variance in questionnaire responses (cognitive coping
and suppression, helplessness, diverting attention and
praying). This questionnaire is a valid and reliable tool
for chronic pain patient assessment.28
Data analysis
An a priori power analysis based on a previous open
study data of reduction in VAS for pain with IT
therapy21 computed a sample size of 24 (12 per group)
that would provide 80% power at the 5% signiﬁcance
level to detect a difference in the means of 1.2 SDs
(unpaired t test) or a difference between the two pro-
portions 20% and 80% (Fisher’s exact test). The power
analysis was based on a study which compared one
group receiving morphine with one group receiving
placebo (saline). The difference in means in the pilot
study (5.1–0.91=4.19) was not used as the basis for the
power calculation as the difference in the pilot study was
likely to be larger than the difference observed in the
current study where both groups received morphine.
A difference in the means of 1.2 SDs was considered as
a realistic estimate since we allowed for the effect to be
much smaller than that observed in the pilot study (2.6
SDs if the SDs of 1.3 and 1.9 are pooled). Imputation
methods were not used since the dropout rate in the
group randomised to have IT dose reduction was 70%.
This high dropout percentage rate would bias the results
regardless of the imputation technique employed.
Therefore, we followed an intention-to-treat protocol; all
participants were included in the analysis and this was
limited to within-group and between-group comparisons
of baseline and ﬁnal observation scores.
The Kolmogorov-Smirnov test was performed to test nor-
mality of numerical data. The majority of the numerical
data was not normally distributed and attempts to trans-
form the data were unsuccessful. Therefore, differences
between patient baseline characteristics were performed
using the Mann-Whitney U test. Differences between the
baseline and last observation scores were evaluated using
the Wilcoxon signed-ranks test. Categorical variables were
investigated using Fisher’s exact test. Data were reported as
the median (minimum–maximum). Statistical signiﬁcance
was judged at the 5% level. Statistical tests were performed
using the Statistical Package for the Social Sciences (SPSS)
software (V.19.0, SPSS Inc, Chicago, Illinois, USA).
RESULTS
Between 2006 and 2011, 24 patients were assessed for eli-
gibility and 9 declined to participate. Following inclusion
Figure 1 Flow chart of patient participation.
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in the study of 15 patients, it was observed that a high rate
of patients withdrew from the research (ﬁgure 1). Owing
to the large number of withdrawals, a ﬁrst interim analysis
was undertaken just beyond the halfway point, which
revealed that the withdrawals were all from the group ran-
domised to have dose reduction. The dropout rate in the
group randomised to have IT dose reduction was 70%
and there were no dropouts in the patients allocated to
the control (no dose reduction) group. One participant
left the study following week 1, three patients withdrew
after week 2, two participants after week 5 and one
patient after week 7. The IT opioid dose in the patients
who withdrew from the study was reduced from a median
of 1.6 mg/day (0.625–5.5) to 1.15 mg/day (0.4–2.8),
which corresponds to a decrease of 36% (20–79) in the
IT opioid dose. The reason for dropping out from the
study was related to a worsening of pain for all the partici-
pants. Calculation of the dropout rates between groups
indicated a signiﬁcant statistical difference (p=0.026).
Recruitment ceased at that moment.
The patients recruited comprised eight men (53.3%)
and seven women (46.7%) with a median age at the
moment of enrolment in the study of 58 years (45–68).
The median duration of the ITDD system therapy prior
to participation in this study was 26 months (12–180).
The pain syndrome was mechanical nociceptive caused
by degenerative low back pain in ﬁve (33.3%) of the par-
ticipants; visceral nociceptive due to postsurgery
abdominal pain in one (6.7%) patient and mixed noci-
ceptive–neuropathic following failed back surgery syn-
drome in nine (60%) participants. The ﬁve patients in
the control group comprised two with mechanical back
pain and three with failed back surgery syndrome; the
10 in the intervention group comprised 3 with mechan-
ical back pain, 6 with failed back surgery syndrome and
1 with postsurgery abdominal pain. All patients had
been on systemic opioids prior to pump implantation
and thereafter only took opioids intrathecally. The pre-
parations differed and the equivalent oral morphine
dose prior to implant ranged from 20 to 240 mg mor-
phine equivalent per day (tables 1 and 2).
There were no statistically signiﬁcant differences
between groups at baseline for age, gender, duration of
therapy prior to study, adjuvant IT medications, VAS,
ODI, HAD scale and CSQ (table 1). The IT opioid dose
administered at study entry was signiﬁcantly higher in
the control group (median, Mdn=4.625) than in the
intervention group (Mdn=1.612), a chance ﬁnding,
U=7.00, p=0.028; r=−0.57. A comparison of baseline
scores between patients who completed the study and
those who did not demonstrates non-signiﬁcant differ-
ences for all the variables, including the IT dose admi-
nistered at the start of the investigation (table 2).
The VAS change between baseline and the last observa-
tion was lower in the control group (Mdn=11) than in the
intervention group (Mdn=30.5), although not statistically
Table 1 Baseline characteristics of the patients according to randomisation groups
Characteristics Control group (n=5) Intervention group (n=10) Z-test statistic p Value
Age (years) 55 (45–59) 64 (52–68) −1.719 0.095
Gender (male/female) 4/1 4/6 0.282
Duration of therapy (months) 66 (22–88) 20.5 (12–180) −1.191 0.265
Preimplant oral morphine dose (mg/day) 60 (20–120) 50 (40–240) −0.638 0.579
Morphine dose (mg/day) 4.625 (2.125–5.65) 1.612 (0.625–5.5) −2.205 0.028
Adjuvant intrathecal medication (yes/no) 4/1 5/5 0.580
Bupivacaine dose (mg/day) 3.190 (2.05–4.433) 2.050 (1.65–2.122) −1.715 0.111
Visual analogue scale 59 (0–69) 49.5 (10–64) −1.043 0.323
Oswestry Disability Questionnaire 54 (12–64) 55.85 (42–72) −0.677 0.529
Hospital Anxiety and Depression (HAD) scale
HAD anxiety 8 (2–16) 7.5 (1–12) −0.369 0.745
HAD depression 7 (2–11) 7.5 (2–15) −0.802 0.450
Coping Strategies Questionnaire
Diverting attention 12 (0–29) 11.5 (0–31) −0.147 0.918
Reinterpreting pain sensation 0 (0–19) 3.5 (0–26) −0.477 0.690
Catastrophising 7 (2–31) 22 (1–27) −0.147 0.911
Ignoring pain sensations 8 (3–21) 8 (0–28) −0.221 0.862
Praying or hoping 14 (2–26) 18.5 (0–30) −0.366 0.753
Coping self-statements 25 (15–30) 19 (2–32) −0.954 0.375
Increasing activity level 16 (3–30) 13.5 (6–29) −0.366 0.753
Control over pain 2 (1–5) 3 (1–4) −0.301 0.757
Ability to decrease pain 2 (1–4) 3 (2–4) −0.846 0.543
Cognitive coping and suppression 32 (18–70) 32.5 (6–83) −0.293 0.833
Helplessness −7 (−14 to 10) 2 (−36 to 11) −0.806 0.458
Diverting attention and praying/hoping 26 (2–54) 31.5 (0–56) −0.440 0.698
Median (minimum–maximum); gender and adjuvant intrathecal medication were evaluated using Fisher’s exact test; all other variables were
analysed using the Mann-Whitney U test (Exact sig. (2-tailed)); statistical significance represented at p<0.05.
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signiﬁcant, Z=−1.839, p=0.070; r=−0.47 (table 3). There
were no statistically signiﬁcant differences between the ran-
domised groups in the changes detected for ODI, HAD
scale anxiety and depression and all items of CSQ between
the baseline score and the ﬁnal observation.
Within-group comparisons were also carried out
(table 4). Statistically signiﬁcant differences for VAS were
observed between baseline and the last observation in
the group randomised to have dose reduction (interven-
tion) but not in the control group (p=0.188). VAS was
signiﬁcantly lower at baseline (Mdn=49.5) than at the
last observation (Mdn=77.5) for the intervention group,
Z=−2.805, p=0.002; r=−0.627 (ﬁgure 2). The ODI scores
at baseline (Mdn=55.85) were signiﬁcantly lower than at
the last observation (Mdn=68.40) for the group allo-
cated to have dose reduction, Z=−2.201, p=0.027;
r=0.492. No statistically signiﬁcant differences were
observed for ODI in the control group (p=0.063). There
were no statistically signiﬁcant changes detected for
HAD scale anxiety and depression and all items of CSQ
in either randomised group between the baseline score
and the ﬁnal observation.
The calculation of clinical changes based on the
VAS scores indicated non-signiﬁcant clinical changes in
10% of the patients in the dose-reduction group
(intervention); minimally clinically important changes
(≥10% and <30%) were observed in 20% of the parti-
cipants randomised to this group, moderately import-
ant increase in pain (≥30% and <50%) in 40% of the
participants and substantially important increase in
pain (≥50%) in 30% of the patients. For the group
where the morphine dose remained the same
Table 3 Changes between baseline and the last observation
Control group (n=5) Intervention group (n=10) Z-test statistic p Value
VAS 11 (−4–40) 30.5 (2–77) −1.839 0.070
ODI 12 (4–18) 6 (−2–30) −1.070 0.311
HAD anxiety 1 (−6–3) 0.5 (−3–5) −0.523 0.653
HAD depression 0 (−1–3) 0 (−3–6) −0.074 0.959
Median (minimum–maximum); variables were analysed using the Mann-Whitney U test (Exact sig. (2-tailed)).
HAD, Hospital Anxiety and Depression scale; ODI, Oswestry Disability Index; VAS, visual analogue scale.
Table 2 Baseline characteristics of the patients according to completion of study
Characteristics Complete (n=8) Incomplete (n=7) Z-test statistic p Value
Age (years) 56.5 (45–68) 64 (53–66) −1.102 0.296
Gender (male/female) 6/2 2/5 0.132
Duration of therapy (months) 25 (15–88) 27 (12–180) −0.081 0.960
Preimplant oral morphine dose (mg/day) 60 (20–120) 60 (40–240) −0.241 0.869
Morphine dose (mg/day) 3.065 (1.02–5.65) 1.6 (0.62–5.5) −1.273 0.232
Adjuvant intrathecal medication (yes/no) 5/3 4/3 1.000
Bupivacaine dose (mg/day) 2.5 (1.7–4.25) 2.085 (1.86–2.12) −0.735 0.556
Visual analogue scale 44.5 (0–69) 54 (23–64) −0.522 0.632
Oswestry Disability Index 53 (12–64) 57.7 (42–72) −1.222 0.244
Hospital Anxiety and Depression (HAD) scale
HAD anxiety 7 (2–16) 8 (1–12) −0.116 0.934
HAD depression 9 (2–15) 7 (2–12) −0.816 0.447
Coping Strategies Questionnaire
Diverting attention 12 (0–29) 13 (0–31) −0.501 0.649
Reinterpreting pain sensation 0 (0–19) 3.5 (0–26) −0.466 0.714
Catastrophising 22 (2–31) 15 (1–27) −0.575 0.608
Ignoring pain sensations 8 (0–21) 8 (0–28) −0.215 0.861
Praying or hoping 15 (2–30) 18.5 (0–25) −0.358 0.760
Coping self-statements 24 (13–30) 19 (2–32) −0.358 0.755
Increasing activity level 16 (3–30) 13.5 (6–29) −0.143 0.916
Control over pain 2 (1–5) 3.5 (2–4) −1.101 0.317
Ability to decrease pain 2 (1–4) 3 (2–4) −1.050 0.386
Cognitive coping and suppression 32 (12–70) 32.5 (6–83) −0.000 1.000
Helplessness −5 (−14 to 11) 0 (−36 to 10) −0.215 0.868
Diverting attention and praying/hoping 27 (2–54) 31.5 (0–56) −0.287 0.809
Median (minimum–maximum); gender and adjuvant intrathecal medication were evaluated using Fisher’s exact test; all other variables
analysed using the Mann-Whitney U test (Exact sig. (2-tailed)); statistical significance represented at p<0.05.
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(control), non-signiﬁcant changes were observed in
40% of the sample, minimally clinically important
changes (≥10% and <30%) in 40% of the participants
and one patient (20%) had a clinically substantial
increase in pain.
DISCUSSION
This RCT of IT opioid therapy in chronic non-malignant
pain has demonstrated differences in pain relief
between dose reduction and dose maintenance. It lends
support to the efﬁcacy of this therapy, which until now
has not been subject to controlled trials.
A power analysis indicated that 24 patients would need
to be included in the study to obtain a power of 0.8;
however, owing to the high number of withdrawals, we
undertook an interim analysis in which we found that
the withdrawals were all in the dose-reduction arm. The
attrition rate of 70% in the group randomised to have
reduction also indicates that the treatment seems to be
effective. Statistically signiﬁcant differences between the
arms were observed and the study was stopped.
Although not statistically signiﬁcant, the VAS change
between baseline and the last observation was lower in
the control group than in the reduction group.
Within-group VAS and ODI differences were statistically
signiﬁcant between baseline and the last observation for
the intervention arm with statistically signiﬁcant greater
pain and worsened disability in the dose-reduction arm.
Clinically important changes indicating an increase in
Table 4 Within-group analysis for the visual analogue
scale (VAS) and Oswestry Disability Index (ODI)
VAS ODI
Control group
Baseline (n=5) 59 (0–69) 54 (12–64)
Last observation 70 (40–83) 64 (30–74)
Test statistic Z=−1.625 Z=−2.032
p Value 0.188 0.063
Intervention group
Baseline (n=10) 49.5 (10–64) 55.85 (42–72)
Last observation 77.5 (57–100) 68 (48–84)
Test statistic Z=−2.805 Z=−2.201
p Value 0.002 0.027
Median (minimum–maximum); variables were analysed using the
Wilcoxon test (Exact sig. (2-tailed)).
Figure 2 Individual visual
analogue scale scores at
baseline and the final observation
for the control group (n=5) and
reduction group (n=10).
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pain intensity were observed in 90% of the patients ran-
domised to dose reduction (intervention). These
changes were moderately important (≥30% and <50%)
in 40% of the patients and substantially important
(≥50%) in 30% of the participants.
Signiﬁcant differences between groups at enrolment
were observed for the morphine dose. The dose main-
tenance group (control) was found to have a signiﬁ-
cantly higher starting opioid dose. This mirrored the
statistically insigniﬁcant trend towards the longer dur-
ation of IT therapy. It is possible that this group had
greater levels of pain than the intervention group for
the same dose of opioid and/or that with a longer dur-
ation of therapy, the dose had increased with time, as a
small increase in opioid dose may be necessary to main-
tain an adequate pain control and recent observations
from our unit indicate that signiﬁcant differences cease
following year 3 of therapy, suggesting stability.12 When
dose escalation occurs, it is usually due to tolerance, pro-
gress of the disease34 or opioid-induced hyperalgesia.35
All participants had stable levels of opioid delivery, as
evidenced by no change in the delivered dose at recent
reﬁlls before investigation, and all reported analgesia
with comparable pain scores (VAS). In using percentage
dose reduction in this study, we anticipated overcoming
a potential bias from this. Furthermore, no signiﬁcant
differences were observed at enrolment between those
who completed the study and those who withdrew
before completion, indicating that the initial opioid
dose did not impact on the dropout rate. We had pur-
posely chosen a small decrease in dose (20%) to prevent
the patients suffering from any withdrawal symptoms
and none occurred. This parallels the experience of
Rauck et al36 in a study of opiate reduction within the
context of investigating ziconotide. In this study, there
was a 3-week weaning period prior to entering the trial,
and thus the weekly reduction in IT opioids would there-
fore be approximate to 30%. The weaning process was
successful in 92.9% of the patients; only 14 dropped out
due to the inability to tolerate withdrawal, adverse
events, non-compliance or patient’s request.
This study has recognised weaknesses of small sample
size as well as being conducted in a single centre. The
sample size was inferior to the 24 patients indicated by
the a priori power analysis as the study was stopped
when an interim analysis was conducted due to the large
number of dropouts and revealed signiﬁcant differences
for withdrawals between groups. There was an imbalance
in the number of patients in each group. The patients
were randomised as a single block of 24, thus ensuring
that in a sample of 24 there would be 12 in each group.
Randomisation of smaller blocks would ensure that
there were equal numbers in each group for smaller
sample sizes as well (eg, if we had used a block size of 6,
we would have had equal numbers in each group after
6, 12, 18 and 24 patients had been randomised). With
our single block of 24, the chance of getting a split as
uneven as 10 and 5 after 15 patients was about 9%. This
RCT was conducted in a single centre. Selection for
therapy followed the national guidelines8; however, their
interpretation may vary in clinical practice even within
the same country in the psychosocial domains of pain.
Dose-titration strategies may differ across treatment
centres. Different centres have reported average doses of
4.7 mg/day at an average of 3.4 years,37 7.42 mg/day at
29.14 months,38 9.6 mg/day at year 139 and 12.2 mg/day
at year 3.40 This may lead to different levels of opioid
delivery for which the sensitivity to dose reduction may
differ.
The strengths of this study were not looking in the
period following ITDD implantation because we consid-
ered that this period is confounded by the need for
dose titration and the non-speciﬁc psychological effects
of a major intervention. In investigating patients with IT
delivery for a minimum of 12 months, we were able to
focus on the evaluation of long-term efﬁcacy of IT
opioid therapy. To our knowledge, this is the ﬁrst rando-
mised, double-blind controlled study of this therapy in
non-cancer pain. The ﬁndings of our RCT suggest the
efﬁcacy of IT morphine for the management of chronic
non-cancer pain. Statistically and clinically signiﬁcant
increases in pain intensity were observed for patients
randomised to have IT morphine dose reduction. In the
light of these results, investigation of different popula-
tions and larger cohorts are recommended.
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